PEB pacific edge limited

Ann: GENERAL: PEB: Japan grants PE patent for colorectal cancer prognostic

  1. lightbulb Created with Sketch. 2
    • Release Date: 25/09/14 09:34
    • Summary: GENERAL: PEB: Japan grants PE patent for colorectal cancer prognostic
    • Price Sensitive: No
    • Download Document  7.09KB
    					PEB
    25/09/2014 09:34
    GENERAL
    
    REL: 0934 HRS Pacific Edge Limited
    
    GENERAL: PEB: Japan grants PE patent for colorectal cancer prognostic
    
    25 September 2014
    
    Japan grants Pacific Edge patent for colorectal cancer prognostic technology
    
    The world's second largest single biomedical market, Japan, has awarded
    Pacific Edge a patent for its colorectal cancer prognostic technology.
    Pacific Edge Chief Executive Officer David Darling says the issue of the
    patent in Japan is a significant step for the Company by providing
    intellectual property protection in the country where colorectal cancer is
    the most prevalent cancer.
    
    "Currently our focus is on accelerating the roll-out of the Company's first
    commercial molecular diagnostic test, Cxbladder Detect, in the USA, the
    world's largest health care market. We are gaining commercial traction and as
    milestones are attained there, the opportunity to launch the Cxbladder system
    into other markets and bring to market further developments of our
    intellectual property, such as our colorectal cancer technology, become
    attractive."
    
    "We are on track to launch our second product, Cxbladder Triage, into the NZ
    market late this year. This is an exciting time for Pacific Edge."
    
    Colorectal cancer is overall the most prevalent cancer in Japan, the second
    highest in men and third highest in women. Its incidence in Japan has
    increased dramatically over the last 30 years which has been attributed to
    changing lifestyles and diets.
    
    Pacific Edge's colorectal cancer prognostic technology is targeted to enable
    the detection of aggressive cancer in patients already diagnosed with
    colorectal cancer. This prognostic test in development is expected to provide
    clinicians with a significantly improved capability to determine the
    aggressiveness of Stage II and Stage III colorectal cancer. The test results
    will enable clinicians to predict progression and provide patients with a
    more specific treatment following surgery. Pacific Edge's colorectal cancer
    prognostic gene signature is in late stage development and on completion will
    become another commercial product for the Company, joining the Cx family as
    Cxcolorectal.
    
    Presently, patients with Stage II disease are generally not treated with
    adjuvant chemotherapy as it is not possible to identify the subset of
    patients who will have aggressive disease. In the five major European
    countries, the USA and Japan, approximately 430,000 individuals are diagnosed
    with colorectal cancer every year. Of those diagnosed cases approximately
    280,000 patients are diagnosed with Stage II and Stage III progressions of
    the cancer. Approximately 30% of the patients with Stage II and roughly 50%
    of those with Stage III experience disease progression including distant
    metastasis of the liver and lung or local recurrence within three to five
    years after surgery. If the cancer spreads to distant organs, the five-year
    survival rate for these patients is approximately 8% making the early
    detection of those patients with an aggressive disease a significant medical
    opportunity for clinicians and patients. Cxcolorectal will provide clinicians
    with a valuable tool to help identify those patients at greatest risk who
    will then be able to be more appropriately targeted for adjuvant chemotherapy
    in addition to surgery.
    
    For more information contact:
    
    David Darling
    Chief Executive Officer
    Pacific Edge Ltd
    P: +64 (3) 479 5800
    
    ABOUT PACIFIC EDGE
    
    Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
    company specialising in the discovery and commercialisation of diagnostic and
    prognostic technology for the early detection and monitoring of cancer.
    Products in development and in clinical trials are accurate and simple to use
    genomic and proteomic tools for the earlier detection, improved
    characterisation and better management of gastric, bladder, colorectal
    cancers and melanoma. The company has completed and released its first
    product for the detection of bladder cancer, Cxbladder, and is actively
    marketing the product to physicians and clinicians in New Zealand, Australia
    and the USA and soon in Spain.
    
    www.pacificedge.co.nz
    
    ABOUT PACIFIC EDGE DIAGNOSTICS
    
    Pacific Edge takes its exciting cancer detection tests to market through its
    wholly owned subsidiaries, Pacific Edge Diagnostics NZ Ltd and Pacific Edge
    Diagnostics USA Ltd, and selected commercial partners in Australia and Spain,
    Healthscope and Oryzon respectively.
    
    www.pacificedgedx.com
    
    ABOUT Cxbladder
    
    The Company's first product to reach the market is Cxbladder, a proprietary,
    accurate molecular diagnostic test that enables the non-invasive detection of
    bladder and other urinary tract cancers from a small volume of urine.
    Cxbladder was commercialised in New Zealand and Australia in 2012 and the USA
    in 2013 as a Laboratory Developed Test (LDT).  It provides physicians and
    clinicians with a quick, cost effective and accurate measure of the presence
    of the cancer, and provides urologists with the opportunity to reduce their
    reliance on the need for invasive tests such as cystoscopy. The Cxbladder
    cancer detection test has been validated by a multicentre, international
    clinical study.  Results published in the Journal of Urology (Sept 2012) show
    that Cxbladder out-performed all of the benchmark technologies in the
    clinical trial and detected nearly all of the tumours of concern to a
    urologist; At a performance of 82% sensitivity and 85% specificity the test
    sees 100% of T1, 100% of T2, 100% of T3, 100% of Tis and 100% of upper
    urinary tract cancers as well as greater than 95% of high grade tumours.
    
    www.cxbladder.com
    
    ABOUT BLADDER CANCER
    
    Globally, bladder cancer has the 9th highest incidence and the 4th highest
    incidence for men. One of the early symptoms of bladder cancer is the
    presence of blood in the urine, haematuria. People with haematuria often
    present to their general practitioner before being referred on to a
    urologist.
    
    There are a number of 'at risk' occupations that have shown a much higher
    incidence of bladder cancer. Fire fighters and fire control officers have
    shown in a US study to have a twice the incidence of bladder cancer over non
    fire fighters. Smoking is a significant contributing factor (over 50% in
    males and 33% in females, and approximately one of every two new incidences
    of bladder cancer is linked to smoking). Exposure to certain industrial
    chemicals or carcinogens increases risks for some occupations e.g.
    hairdressers, painters, printers, fire fighters and metal workers and
    chemical engineers. Incidence increases with age so the older you are, the
    greater the potential for bladder cancer.
    
    Bladder cancer has a very high recurrence rate of approximately 50%-70% with
    up to 30% of these recurring as later stage tumours. This is a higher
    recurrence than for skin cancer! However, bladder cancers are highly
    treatable, especially if detected in the early stages. If diagnosed early
    there is a much higher probability of survival for early stage tumours
    relative to later stage tumours. This makes timely and regular surveillance
    and monitoring of this cancer a key element of the clinical process and of
    the individual's annual healthcare plan.
    End CA:00255683 For:PEB    Type:GENERAL    Time:2014-09-25 09:34:11
    				
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
10.4¢
Change
0.002(1.96%)
Mkt cap ! n/a
Open High Low Value Volume
10.4¢ 10.6¢ 10.4¢ $20.03K 191.3K

Buyers (Bids)

No. Vol. Price($)
0 962 10.4¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 10802 0
Last trade - 12.44pm 08/08/2025 (20 minute delay) ?
PEB (NZSX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.